Published online Thursday in the journal Nature Medicine, the study showed that the virus had been suppressed to harmless "background levels" in the vaccinated monkeys.
"The next step is to figure out how to make it compatible for human use. We are in the process of adapting that to a cell line where it could be made and tested in (preliminary) phase one trials," Nagel said.
Phase three trials designed to verify efficacy could follow within another two years, he added.
Chikungunya gets its name from a Swahili word meaning "that which bends up," a reference to arthritis-like symptoms that leave victims stooped. The disease also causes intense headaches and fever.
An outbreak on the French Indian Ocean island of Reunion in early 2005 infected a quarter of the population in less than two years, causing some 250 deaths.
It is rampant today in India, Thailand and other parts of southeast Asia, Nagel said.
Source-AFP
THK